Quintrio
Home

Stock overview

Sinovac Biotech, Ltd

SVA

Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.

Market snapshot unavailable. Historical chart data may still be available.

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for SVA.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SVA, quarterly periods
Line itemQ2 FY2020 Jun 30, 2020Q2 FY2019 Jun 30, 2019Q4 FY2015 Dec 31, 2015Q4 FY2014 Dec 31, 2014Q4 FY2013 Dec 31, 2013Q4 FY2012 Dec 31, 2012Q4 FY2011 Dec 31, 2011Q4 FY2010 Dec 31, 2010
Revenue$52.33M$64.05M——————
Cost of revenue$7.56M$6.09M$0$0$0$0$0$0
Gross profit$44.77M$57.95M——————
Selling, general and administrative$29.79M$30.19M——————
Research and development$14.45M$6.35M——————
Total operating expenses$45.18M$36.91M——————
Operating income-$412K$21.04M——————
Interest expense-$373K-$166K——————
Income before taxes-$101K$21.57M——————
Income taxes$1.17M$4.47M——————
Net income-$1.27M$17.1M——————
Net income attributable to common shareholders-$5.26M$10.66M——————
EBITDA$1.2M$22.28M$0$0$0$0$0$0
Basic earnings per share-$0.05$0.11——————
Diluted earnings per share-$0.05$0.09——————

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players

The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.

GlobeNewswire Inc.

SINOVAC Management Statement Regarding Auditor Resignation

Sinovac Biotech Ltd. (NASDAQ: SVA) is facing a crisis as its external auditor has resigned, leading to a delay in filing its annual report with the SEC. The company's current board is reviewing actions taken by the former board, causing uncertainty and disruption to the company's operations and governance.

GlobeNewswire Inc.

Respiratory Disease Vaccines Market Research Report 2025: Analysis and Forecast (2020-2030) Featuring GSK, Johnson & Johnson Services, Pfizer, Sanofi, Serum Institute of India, SINOVAC Biotech & More

The global respiratory disease vaccine market is expected to grow from $94.6 billion in 2024 to $101.56 billion by 2030, driven by factors such as the increasing prevalence of respiratory diseases, the aging population, and government vaccine mandates and recommendations.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jul 8, 2025$55.00Jul 7, 2025special

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.